Page 34 - Anne Donohoe News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Aion Therapeutic s Proprietary Mushroom Preparations Shown Effective in Killing Breast Cancer Cells
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
The Very Good Food Company Inc : The Very Good Food Company Announces Partnership with Green Spoon Sales to Accelerate U S Retail Growth
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
NEW YORK, April 7, 2021 /PRNewswire/ atai Life Sciences ( atai or the Company ), a global biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, has acquired a majority stake in Delaware based Psyber, a company dedicated to developing interventions to improve various mental health disorders and induce behavioural changes through brain computer interface (BCI)-enabled digital therapeutics (DTx).
EEG-based BCI devices record electrical activity in the brain for real-time interpretation of emotional, behavioural, and mental states. Traditionally, the main goal of BCI has been to replace or restore useful functions to people disabled by neuromuscular disorders. However, recent studies have shown that the technology may have useful applications for mental health disorders as it allows for a direct decoding of emotional experience from neural activity.
Recognify Life Sciences to Commence Phase 2a Study in Cognitive Impairment Associated with Schizophrenia
News provided by
Share this article
Share this article
NEW YORK, April 6, 2021 /PRNewswire/ Recognify Life Sciences, Inc. (Recognify), an atai Life Sciences (atai) platform company focused on developing treatments for cognitive impairment with initial efforts targeting Cognitive Impairment Associated with Schizophrenia (CIAS), today announced it has initiated a Phase 2a study for its lead compound RL-007, after receiving IND clearance from the Food and Drug Administration to commence clinical trials in the United States in this indication.
Schizophrenia is a mental health disorder primarily characterized by hallucinations, delusions, and disordered thinking. This condition effects over 21 million people globally and approximately 2.4 million people in the United States, with around 300,000 new cases being diagnosed each year in the US. Cognitive deficits are frequently pre
Arizona s Governor: Harris Worst Possible Choice to Oversee Border
businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.